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1 Introduction 
1.1 Conjugated linoleic acid (CLA) 
Conjugated linoleic acid (CLA) is a collective term for a group of positional 
and geometrical isomers of linoleic acid with a conjugated double bond system. 
It is formed in the digestive tracts of ruminant animals such as cows, sheep and 
goats by fermentative bacteria. Butyrivibrio fibrisolvens is a fermentative 
anaerobic bacterium that isomerizes cis-9,trans-12-octadecenoic acid (linoleic 
acid) to cis-9,trans-11-octadecenoic acid (cis-9,trans-11-CLA), followed by the 
hydrogenation of the cis-double bond of the conjugated diene to yield trans-11-
octadecenoic acid (trans-vaccenic acid) (figure 1). Trans-vaccenic acid is further 
converted to cis-9,trans-11-CLA within mammalian cells through stearoyl-CoA 
desaturase (SCD), a δ -9 desaturase [1]. In addition to rumenal bacteria, enteric 
bacteria such as Bifidobacterium species and Lactobacillus species can 
produce various CLA isomers from linoleic acid [2]. The most common sources 
of CLA are beef, dairy products and partly hydrogenated vegetable oils [3]. The 
daily intake of CLA has been calculated for various countries and estimated at 
several hundred mg/day in a typical diet [4]. The cis-9,trans-11 (c9,t11)- and 
trans-10,cis-12 (t10,c12)-CLA isomers are the major dietary forms of CLA, but 
lower levels of other isomers such as trans-9,trans-11 (t9,t11)-CLA are also 
present in CLA food sources (figure 2) [5].  
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Figure 1: Formation of c9,t11-CLA in the digestive tracts of ruminant animals by Butyrivibrio 
fibrisolvens. 
 
                 
t10,c12-CLA
 t9,t11-CLA
c9,t11-CLA
 
Figure 2: CLA isomers of major and minor abundance. 
 
Major interest in CLA had emerged about 20 years ago, because CLA 
obtained from lipids extracted from barbecued beef displayed anti-carcinogenic 
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properties [6]. These anti-carcinogenic activities of CLA have been confirmed in 
a chemically induced rat mammary tumor model with an effective range of 0.1-
1.0% CLA in the diet [7]. The growth inhibitory effects of CLA have also been 
studied in various human cancer cells including hepatoma, colorectal, breast 
and lung cancer. C9,t11-CLA, t10,c12-CLA and a CLA mixture inhibited 
proliferation of these cancer cells [8]. These reported effects from animal 
studies and in vitro studies are supported by several findings in humans such as 
an inverse relationship between milk consumption and breast cancer risk in 
woman [9]. Further, dietary CLA intake and serum CLA levels of Finnish woman 
were significantly lower in cancer patients than in controls [10].  
These very promising findings led to various studies investigating 
beneficial health effects of CLA. Most studies use animal models and a mixture 
of the two major CLA isomers. It has been shown that feeding mice a mixture of 
c9,t11- and t10,c12-CLA mediates protection from chemically induced 
inflammatory bowel disease (IBD). The CLA mixture activates nuclear 
peroxisome proliferator activated receptors (PPARs) γ and δ and represses 
expression of inflammatory genes such as tumor necrosis factor (TNF) α and 
nuclear factor-kappa B (NFκB), while inducing the immuno-regulatory cytokine 
transforming growth factor (TGF) β 1 [11]. Studies on CLA supplemented pigs 
support these findings. Thus, the onset of IBD is delayed and colitis less severe. 
Moreover the growth suppression diminished in pigs fed CLA correlating with 
the induction of colonic PPARγ and downregulation of TNFα [12]. 
Several studies have shown that CLA inhibits the development and 
progression of atherosclerosis. A mixture of the major occurring isomers c9,t11- 
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and t10,c12-CLA induced a profound resolution of pre-established 
atherosclerosis in mice. CLA negatively regulated the expression of pro-
inflammatory genes and induced apoptosis in atherosclerotic lesions primary via 
activation of PPARα and γ [13]. Interestingly, another study describes a 
selective isomer-dependent effect of conjugated linoleic acid on atherosclerotic 
lesion development. Supplementation of apolipoprotein E deficient mice with 
c9,t11-CLA diminished, whereas t10,c12-CLA promoted atherosclerosis [14].  
However to date, no study has determined the effect of CLA on atherosclerosis 
in humans. Several studies in humans found a lipid lowering and therefore anti-
atherosclerotic effect, but the results of different studies are still inconsistent 
[15].  
The underlying molecular mechanisms that lead to most physiological 
effects of CLA are a result PPARα, γ and δ activation. PPARs are well 
described ligand activated nuclear transcription factors that play important roles 
in cellular differentiation, cancer, insulin sensitization, atherosclerosis and 
several metabolic diseases [16]. CLA isomers are high affinity ligands and 
activators of peroxisome proliferator-activated receptors [17]. 
CLA seems to have various health benefits, but there is a marked variation 
between findings of different studies. This variation reflects the isomer specific 
effect of the individual CLA isomers. The composition of CLA mixtures strongly 
influences its biological and physiological effects. 
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1.2 ATP-binding cassette transporter G1 (ABCG1) 
The ATP-binding cassette (ABC) transporters are a large super-family of 
trans-membrane proteins that facilitate the transport of a wide variety of 
substrates across cellular membranes. The human superfamily containing 48 
ABC-transporters is divided into seven subfamilies (A-G). All ABC transporters 
use ATP to generate the energy required for the transport of metabolites across 
membranes. Structurally, they fall into two groups, full size transporters having 
two similar structural units joined covalently and half-size transporters of single 
structural units that form active heterodimers or homodimers. ABCG1 belongs 
to the family of half size transporters, it contains one trans-membrane domain 
consisting of six trans-membrane spanning α-helices, and an ATP-binding 
cassette (figure 3). ABCG1 mRNA and protein are broadly expressed with high 
levels in macrophages [18; 19]. 
                     
Figure 3: Domain organization of ABCG1 from [20]. 
  
ABCG1 is a mediator of macrophage cholesterol efflux to mature high 
density lipoproteins (HDLs). Macrophages lacking ABCG1 expression have 
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impaired cholesterol efflux to HDL but not to lipid-free apolipoprotein AI (ApoAI) 
in vitro [21-23]. Cholesterol efflux from macrophages to ApoAI as acceptor 
particle is mediated by ABCA1 [24]. In contrast to ABCA1, which transports also 
phospholipids and other lipophilic compounds, ABCG1 is mainly a cholesterol 
transporter with only minor phospholipid transport capacity [25]. ABCA1 and 
ABCG1 have been shown to function cooperatively to remove cholesterol from 
cells in vitro, both transporters promote  macrophage reverse cholesterol 
transport in vivo and are additive in their effects [26; 27]. ABCA1 converts lipid-
poor ApoAI to partially lipidated nascent lipoproteins, which are then effective 
acceptors for cholesterol exported by ABCG1 (figure 4).  
 
                
Figure 4: Cholesterol efflux mediated by ABCA1 and ABCG1. PL,phospholipids; FC, free 
cholesterol; adapted from [28]. 
 
Since ABCG1 mediates cholesterol export in macrophages, it is most 
likely that this transporter is cardioprotective and loss of function is atherogenic. 
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Surprisingly, three studies showed that transplantation of bone marrow from 
ABCG1 deficient mice into atherogenic mice caused only a moderate increase 
or even decreased atherosclerotic lesions [29-31]. Decreased atherosclerosis 
was associated with increased macrophage apoptosis and enhanced 
expression of ApoE and ABCA1. Therefore, it was suggested that potential 
harmful effects of impaired ABCG1 may be compensated by beneficial effects 
on clearing apoptotic cells and increasing other compensatory efflux pathways. 
Various transcripts of ABCG1 are produced as a result of the use of 
alternate exons and alternative promoters. The different transcripts are 
predicted to encode ABCG1 proteins, that differ only at the N-terminus (figure 
5). Current evidence suggests that there is only one major transcript in humans, 
hABCG1-a, which is generated after activation of the second promoter (figure 
6). Its regulatory region contains multiple SP1 binding sites and a consensus 
sequence for binding of sterol regulatory element binding protein (SREBP) [32]. 
hABCG1-a expression and function is repressed by zinc finger protein 202 
(ZNF202) [33]. Variant hABCG-1b is produced after induction of its regulatory 
region with oxysterols and liver X receptor (LXR) ligands, because its promoter 
is made up of two liver X receptor (LXR) response elements [34]. Transcript 
hABCG1-c might be synthesized after activation of a putative promoter 
containing a predicted nuclear factor κB (NFκB) binding site [35].  
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Figure 5: Exon configurations of the human ABCG1 transcripts and predicted proteins. aa, 
amino acid; adapted from [36].  
 
 
Figure 6: ABCG1 regulatory region, adapted from Langmann T., Habilitationsarbeit 2003. 
 
1.3 Sterol regulatory element binding protein (SREBP) 
Lipid homestasis in vertebrate cells is regulated by a family of membrane-
bound transcription factors described as sterol regulatory element binding 
proteins (SREBPs). SREBPs are basic helix loop helix leucine zipper (bHLH-
LZ) transcription factors synthesized as 1150 amino acid inactive precursors 
bound to the membranes of the endoplasmatic reticulum (ER) [37]. SREBP 
precursors are organized into three domains, a N-terminal transactivation 
domain for DNA binding and dimerization, two hydrophobic  transmembrane 
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spanning segments and a C-terminal regulatory domain. Upon activation the ER 
anchored premature SREBP (pSREBP) undergoes a sequential two-step 
cleavage process to release its N-terminal activation domain, designated the 
nuclear SREBP form (nSREBP). Three members of the SREBP transcription 
factors have been described in mammalian species (figure 7). SREBP-1a and 
SREBP-1c are produced from the single gene SREBF-1 through the use of 
alternate promoters and they are identical except the N-terminal trans-activation 
domains. SREBP-1c is expressed in most mouse and human tissues, with high 
levels in macrophages, liver, white adipose tissue, adrenal gland and brain, 
whereas SREBP-1a is mainly expressed in cell lines and in tissues with a high 
capacity of cell proliferation such as spleen and intestine [38]. SREBP-2 is 
derived from the separate gene SREBF-2 and shows a 50% homology with the 
SREBP-1 amino acid sequence. [39]. 
 
          
Figure 7: SREBP genes and isoforms. bHLH-LZ, basic helix loop helix leucine zipper, Pro, 
proline; Ser, serine; TA, trans activation. 
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As indicated in figure 8, SREBP-1c responsive targets in mammalian 
cells include genes of fatty acid metabolism such as fatty acid synthase (FASN) 
or stearoyl-CoA desaturase (SCD), which generate saturated and 
monounsaturated fatty acids, and genes that control triacylglyceride and 
phospholipid biosynthesis such as glycerol 3-phosphat acyltransferase (GPAT). 
SREBP-2 responsive genes include cholesterol biosynthesis enzymes such as 
HMG-CoA synthase (HMGCS) and HMG-CoA reductase (HMGCR) [40]. 
In contrast to mammalian cells, Drosophila and C. elegans express genes that 
encode only a single SREBP, its processing is regulated by phospholipids and 
SREBP targets are enzymes required for saturated fatty acid biosynthesis [41; 
42]. 
 
 
Figure 8: SREBP-2 and SREBP-1c controlled genes and metabolic pathways, from [43]. 
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SREBP-1a and SREBP-2 activation is mainly controlled by proteolytic 
cleavage of SREBP precursors, whereas SREBP-1c activation is mainly 
regulated on the transcriptional level. SREBP-1a and SREBP-2 are inserted into 
the membranes of the endoplasmatic reticulum (ER). Its C-terminal regulatory 
domain binds to the C-terminal domain of the sterol sensitive SREBP cleavage-
activating protein (SCAP) (figure 9). When cells are depleted of sterols, SCAP 
transports SREBPs from the ER to the Golgi apparatus where Site-1 protease 
(S1P) and Site-2 protease (S2P) act to release the N-terminal domain of 
SREBP, the nuclear SREBP (nSREBP), from the membrane. Nuclear SREBP 
enters the nucleus, binds to sterol regulatory elements (SREs) in the promoters 
of target genes and activates transcription. When the cellular cholesterol 
content rises, the SCAP/SREBP complex is no longer incorporated in ER 
transport vesicles, SREBPs do not reach the Golgi apparatus, nSREBP cannot 
be released from the membrane and transcription of target genes is shut off [40; 
43; 44]. 
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Figure 9: Regulation of SREBP-1a and SREBP-2 activation by proteolytic cleavage, from [43]. 
 
In contrast to SREBP-1a and -2, nuclear abundance of SREBP-1c is not 
regulated by cholesterol levels [45]. However, SREBP-1c expression is induced 
by oxysterols and the nuclear transcription factor liver X receptor (LXR). LXR 
can directly promote SREBP-1c transcription through two LXR binding elements 
(LXR-Es) in the SREBP-1c promoter (figure 10) [46]. LXR agonists up-regulate 
SREBP-1c expression in vivo in rodents and in vitro in various cell models, 
including human cells [47; 48].  
SREBP-1c expression is depressed in fasting animals but increases when 
animals are re-fed with a high carbohydrate diet, because it can be induced by 
insulin [49; 50]. The effects of insulin on SREBP-1c expression are mediated by 
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a PI(3)-kinase dependent pathway, but the downstream effectors are unclear 
[51]. 
Remarkably, the SREBP-1c promoter can be directly activated by nuclear 
SREBPs in an auto-regulatory loop, because SREs are present in its regulatory 
region [52]. 
 
                  
Figure 10: Promoter of SREBP-1c and its regulation. LXR-E, LXR binding element; SRE, 
SREBP response element; RXR, retinoid X receptor.  
 
SREBPs affect the development of several human metabolic diseases 
including atherosclerosis, type 2 diabetes, obesity and lipodystrophy. In adipose 
tissue of obese and type 2 diabetic patients, SREBP-1c mRNA expression is 
decreased in comparison to controls [53]. Consistent with this finding weight 
loss in obese patients is associated with an improved insulin sensitivity and 
leads to an increase of SREBP-1c expression in adipose tissue.  
In contrast to the adipose tissue, where SREBP-1c levels are diminished, 
SREBP-1c levels are elevated in the fatty livers of obese and insulin resistant 
mice [54]. Despite the profound insulin resistance of the liver, insulin continues 
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to activate SREBP-1c transcription and protein expression. Elevated SREBP-1c 
increases lipogenic gene expression, enhances fatty acid synthesis, and 
accelerates triacylglyceride accumulation. Thus many individuals with obesity 
and insulin resistance also have fatty livers [43]. 
1.4 Liver X receptor (LXR) 
Liver X receptors (LXRs) are ligand dependent transcription factors 
belonging to the nuclear receptor superfamily of proteins. These proteins 
typically contain a N-terminal transcriptional activation domain, a core zinc 
finger DNA binding domain, a hinge region for receptor dimerization and a C-
terminal ligand-binding domain [16]. LXRs form heterodimers with retinoid X 
receptor (RXR) and then bind to LXR-responsive elements (LXR-Es) in the 
promoters of target genes, which mainly consist of direct repeats of the core 
sequence AGGTCA separated by four nucleotides (DR-4 elements) (figure 11) 
[16]. Within the nucleus, LXR/RXR heterodimers are bound to LXR-Es in the 
promoter of target genes in a complex with co-repressors such as silencing 
mediator of retinoic acid, thyroid hormone receptor and nuclear receptor co-
repressor [55; 56]. In response to binding of ligands, the co-repressor 
compexes are exchanged for co-activator complexes and target gene 
expression is de-repressed and induced.  
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Figure 11: LXR mediated activation of target genes, from [57]. 
 
The liver X receptor (LXR) subfamily consists of two members, LXRα 
and LXRβ. The two LXRs share considerable amino acid sequence homology 
(77%), but their tissue distribution differs. LXRα is highly expressed in liver, 
adipose tissue and macrophages, whereas LXRβ is universally expressed [58].  
LXRs control various genes of reverse cholesterol transport (figure 12). 
The first identified direct target gene for LXRs in mice was cholesterol 7-α-
hydroxylase (Cyp7a1), which encodes the rate limiting a enzyme in hepatic bile 
acid synthesis. Cyp7a1 is up-regulated in response to cholesterol rich diet, 
whereas LXRα deficient mice show no induction of Cyp7a1 expression in 
response to high cholesterol diet [59]. Several ABC transporters, such as 
ABCA1 and ABCG1, which mediate cholesterol efflux of macrophages, and 
ABCG5 and G8, which promote cholesterol excretion into the bile, are 
controlled by LXR [18; 60]. Interestingly, Apolipoprotein E (ApoE), was the first 
gene shown to be regulated in a tissue specific manner by LXR [61]. Its 
expression is induced by LXR in adipose tissue and macrophages, but not in 
liver.  
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Figure 12: LXR and its target genes in reverse cholesterol transport, from [57]. 
 
Additionaly LXRs modulate the expression of several lipoprotein-remodeling 
enzymes, including lipoprotein lipase (LPL), cholesterol ester transfer protein 
(CETP) and phospholipid transfer protein (PLTP) [62-64]. LPL catalyzes the 
hydrolysis of lipoprotein tryglycerides. CETP mediates the transfer of HDL 
cholesterol esters to apoB containing particles for return to the liver. PLTP 
remodels HDL particles into large α-HDL and small pre-β-HDL particle fractions, 
which are efficient acceptors of cholesterol from peripheral cells [65]. Besides 
cholesterol and lipoprotein metabolism, LXRs are also implicated in the control 
of fatty acid metabolism via SREBP-1c as described above.  
Consistent with their physiological roles, endogenous activators of LXRs 
are oxidized cholesterol derivates (oxysterols). The most potent natural 
activators inducing LXR at physiological levels are 22-(R)-, 20-(S)-, 24-(S)-
hydroxycholesterol, 24-(S),25-epoxycholesterol and 27-hydroxycholesterol [66; 
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67]. Whereas most LXR ligands activate both LXRα and β, 24-(S),25-di-
epoxycholesterol and 6α-hydroxy bile acids are selective agonists for LXRα 
[68]. In addition to natural ligands, a number of synthetic LXR ligands have 
been developed. The compounds T0901317 and GW3965 are activators of both 
LXR isoforms [69].  
In contrast to oxidized cholesterol derivatives, that enhance transcriptional 
activity of LXRs, geranyl,geranyl-pyrophosphate, an intermediate of cholesterol 
biosynthesis and unsaturated fatty acids antagonize LXR activation [70]. 
The regulation of LXRα in the liver, adipose tissue, muscle and 
macrophages is mainly controlled by PPARs. PPARα and γ agonists induce 
LXRα in mouse and human macrophages [71]. Additionally, an auto-regulatory 
loop, which is limited to human cells, controls the expression of LXRα [72].  
Recent data indicate multiple roles of LXRs in anti-inflammatory pathways 
that are involved in pathogenisis of cardiovascular and metabolic diseases. A 
recent study addressed the importance of macrophage LXR signaling using 
bone marrow transplantation studies in ApoE and LDLR deficient mice [73]. 
This approach allowed an analysis of LXR null macrophages in the setting of 
normal LXR function in liver and intestine, which led to a significant increase in 
atherosclerosic lesion formation in these mice. These studies provide strong 
evidence that LXR activity in macrophages is an important determinant in the 
development and progression of atherosclerosis. Evidence for the potential 
utility of LXR activation in atherosclerosis has come from intervention studies in 
mouse models. The LXR agonist GW3965 was shown to decrease lesion area 
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approximately 50% in both ApoE and LDLR knockout mice and to increase 
ABCA1 and ABCG1 expression in the atherosclerotic aortas of these mice [74]. 
In addition to enhancing cholesterol efflux through activation of ABCA1 and 
ABCG1, LXR agonist treatment led to an increase of cholesterol-accepting 
lipoproteins to be used as acceptors cholesterol efflux.  
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2 Aims 
Since most studies analyzed the effects of CLA mixtures of different 
composition and purity, the aims of this work were to investigate whether the 
single isomers c9,t11- and t10,c12- and t9,t11-CLA have distinct effects on 
gene expression in human macrophages. Gene expression of t9,t11-CLA 
treated in vitro differentiated human macrophages from three healthy donors 
was examined with Affymetrix U133 Plus 2.0 DNA-microarrays. After validation 
of candidate genes with TaqManTM RT-PCR mRNA expression was compared 
to c9,t11-CLA and t10,c12-CLA treated macrophages. We found a t9,t11-CLA 
specific induction of ABCG1. To characterize this activation in detail, gene 
reporter assays with deletion plasmids of the ABCG1 regulatory region were 
carried out. To investigate the effects of the CLA isomer on ABCG1 function, 
cholesterol efflux was determined in t9,t11-CLA treated human macrophages.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Technical equipment 
2100 Bioanalyzer,     Agilent, Palo Alto, CA, USA 
Autoclave Steam Sterilizer Type 24   Melag, Berlin, Germany 
Biofuge 15R      Heraeus, Hanau, Germany 
Cell culture Incubator 6000    Heraeus, Hanau, Germany 
ELISA-reader       Tecan, Stuttgart, Germany 
Horizontal Shaker GFL-3016    GFL, Großburgwedel, Germany 
Incubator B 6120     Heraeus, Hanau, Germany 
Instant Camera MP4     Polaroid, Offenbach, Germany 
Kodak X-Omat 2000 processor    Kodak, Rochester, NY, USA 
LaminAir Hood       Heraeus, Hanau, Germany 
Liquid Scintillation Counter Wallac 1410   Berthold, München, Germany 
Lumi Imager F1     Boehringer, Mannheim, Germany 
LUMAT LB9501      Berthold, München, Germany 
Megafuge 1.0 R     Heraeus, Hanau, Germany 
Microscope (Visible) Leitz Laborlux S   Leitz GmbH, Wetzlar, Germany 
Milli-Q UF Plus System     Millipore, Bradford, VT, USA 
MiniSpin Plus Centrifuge    Eppendorf, Hamburg, Germany 
Mini Transblot Cell     BioRad, München, Germany 
Nano Drop      PeqLab, Erlangen, Gernany 
Precision Balance Sartorius MD BA 200  Sartorius, Göttingen, Germany 
Power Supply PAC 300     BioRad, München, Germany 
Princeton MicroMax CCD-1317-K/1    Roper Scientific, Trenton, NJ, USA 
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Shaking Incubator GFL-3032    GFL, Großburgwedel, Germany 
Shaking Water Bath Julabo SW-20C   Julabo, Seelbach, Germany 
Stirrer with Heating Surface IKAMAG   Labor Center, Nürnberg, Germany 
SpeedVaq Alpha RVC     Christ, Osterode, Germany 
Sysmex Micro-Cell Counter F-300   Digitana AG, Hamburg, Germany 
Thermocycler Gene Amp PCR System 9600  Perkin Elmer, Uberlingen, Germany 
Thermomixer Comfort     Eppendorf, Hamburg, Germany 
Ultrasonic Disintegrator Soniprep 150   MSE, Watford Herts, United Kingdom 
Ultracentrifuge (fixed angle) J2-21 M/E   Beckman, München, Germany 
Ultracentrifuge L-70      Beckman, München, Germany 
Ultracentrifuge Optima TLX    Beckman, München, Germany 
Vortex-Mixer REAX 2000    Heidolph, Kelheim, Germany 
Zeiss Axiovert S-100 Spectral Microscope   Carl Zeiss, Goettingen, Germany 
 
3.1.2 Consumables 
Cell culture flascs     Nunc, USA 
Cell scraper      Sarstedt, Nümbrecht, Germany 
Cups (0,5, 1,5, 2,0ml)     Eppendorf, Hamburg, Germany 
Falcon Tubes (15, 50ml)    Sarstedt, Nümbrecht, Germany 
Filter tips (2, 10, 20, 200, 1000µl)   Eppendorf, Hamburg, Germany 
Latex gloves      Hartmann, Heidenheim, Germany 
Optical adhesive cover     Applied Biosystems, USA 
Sterile Filter      PALL, USA 
384-Well Thermo-Fast plate    ABgene, UK 
 
3.1.3 Reagents 
Trans-9,trans-11-CLA (98% pure)   Cayman Chemicals (IBL), Hamburg, 
Germany 
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Cis-9,trans-11- CLA (96% pure)    Cayman Chemicals (IBL), Hamburg, 
Germany 
Trans-10,cis-12-CLA (98% pure)   Cayman Chemicals (IBL), Hamburg,  
Germany 
 
3.1.4 Gene Expression Assays 
Gene       Applied Biosystems-ID 
Acetoacetyl-CoA synthetase     Hs00225090_m1 
ATP-binding cassette transporter A1   Hs00194045_m1 
ATP-binding cassette transporter G1   Hs00245254_m1 
7-Dehydrocholesterol reductase   Hs00154732_m1  
Fatty acid synthase      Hs00188012_m1 
Farnesyl-diphosphate farnesyltransferase1  Hs00189506_m1 
Farnesyl diphosphate synthase     Hs00266635_m1 
Insulin induced gene 1      Hs01650979_m1 
3-Hydroxy-3-methylglutaryl-CoA reductase  Hs00168352_m1 
3-Hydroxy-3-methylglutaryl-CoA synthase 1  Hs00266810_m1 
Low density lipoprotein receptor    Hs00181192_m1 
Liver X receptor     Hs00172885_m1 
MID interacting protein 1    Hs00221999_m1 
Phospholipid transfer protein    Hs00272126_m1 
Stearoyl-CoA  desaturase    Hs00748952_s1 
Sterol regulatory element binding protein 1c  Hs00231674_m1 
Vascular endothelial growth factor   Hs00173626_m1 
 
3.1.5 Enzymes, inhibitors and kits for molecular biology  
BCA Protein Assay Kit     Pierce, Rockford, IL, USA 
BigDye Terminator Cycle Sequencing Kit v.1.1  Applied Biosystems, Darmstadt, 
Germany  
ECL+ Western Blotting Analysis System  Amersham Pharmacia Biotech, 
Freiburg, Germany 
Galactosidase enzyme assay    Promega, Madison, AL, USA 
MagNa Pure LC DNA isolation Kit   Roche, Mannheim, Germany  
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Nucleasefree water     Promega, USA   
PCR Purification Kit     Qiagen, Hilden  
QIAamp Blood DNA midi Kit    Qiagen, Hilden, Germany  
QIAprep Spin Miniprep Kit    Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit    Qiagen, Hilden, Germany 
QIAshredder      Qiagen, Hilden, Germany  
Reverse Transcription System    Promega, USA  
RNAse Inhibitor RNase ZAP    Ambion, USA  
RNeasy mini Kit     Qiagen, Hilden, Germany  
RNeasy midi Kit     Qiagen, Hilden, Germany  
TaqMan Universal PCR Master Mix  Applied Biosystems, USA  
 
3.1.6 Cells 
THP-1        ATCC (LGC Promochem) , Wesel, 
Germany 
RAW 264.7      ATCC (LGC Promochem) , Wesel, 
Germany 
3.1.7 Plasmids  
pCMV-nSREBP-1a plasmid, a cytomegalovirus driven expression vector 
encoding amino acids 1-460 of human nuclear SREBP-1a, and pCMV-
nSREBP-1c plasmid, encoding amino acids 1-436 of human nuclear SREBP-1c 
were gifts from Dr. Timothy F. Osborne (Department of Molecular Biology & 
Biochemistry, University of California).  
Deletion constructs of the ABCG1 promotor (-2912/+50bp, -957/+50bp, -
457/+50bp and -234/+50bp) have been described by Langmann et al [32].  
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SREBP-1c-Luc plasmids and the constructs with mutated LXR binding sites 
hLXRE-1mut, hLXRE-2mut, hLXRE-1/2mut were provided by Oberkoffler and 
collegues [75; 76].  
The thymidine kinase (TK)-Luc plasmid was generated by ligating the BglII-
HindIII fragment derived from the pRL-TK vector (Promega) containing the 
herpes simplex virus (HSV) minimal TK promoter region into the pGL3-Basic 
Vector upstream of the luciferase reporter gene. For construction of the 3xSRE-
TK-Luc plasmid, three copies of the SREBP-responsive region of ABCG1 (5`-
TGCCAGGGGTCACCCCACACCGGTGCTG-3`) were inserted into the TK-Luc 
plasmid using the NheI and KpnI restriction sites of its multiple cloning site.  
 
3.2 Methods 
3.2.1 Working with cells 
3.2.1.1 Cell culture and stimulation  
THP-1 cells and RAW 264.7 cells were cultured in RPMI 1640 medium or 
DMEM medium (Sigma) supplemented with 10% fetal calf serum (Gibco BRL), 
100 U/ml penicillin, 100 μg/ml of streptomycin and incubated in 10% CO2 in air 
at 37 °C. THP-1 monocytes were differentiated over night in the presence of 
160 nM PMA prior to treatments and RNA or protein extraction.  
Human monocytes were obtained from healthy donors by leukapheresis and 
counterflow elutriation [20]. The cells were cultured on plastic petri dishes in 
macrophage SFM medium (Gibco BRL) and allowed to differentiate for 4 days 
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in the presence of 50 ng/ml recombinant human macrophage colony stimulating 
factor (MCSF) from R&D Systems. Cells were stimulated with the indicated 
concentration of t9,t11-, c9,t11- and t10,c12-CLA or ethanol as solvent control. 
3.2.1.2 Transfections and reporter gene assays 
THP-1 cells were electroporated with Amaxa`s Nucleofector-Kit-V and RAW 
264.7 cells were transiently transfected with FuGENE 6 (Roche) according to 
the manufacturer`s instructions.  A promoterless pGL3-basic vector served as 
negative control, while a pGL3-control vector containing the CMV promoter was 
used as positive control. A cotransfected  β-galactosidase plasmid was used to 
estimate transfection efficiency. Luciferase assays and β-galactosidase assays 
were carried out 36h after transfections. 
3.2.2 Working with DNA 
3.2.2.1 Isolating and purifying DNA 
Plasmids were purified from overnight cultures with the QIAprep Spin Miniprep 
Kit (Qiagen). PCR-fragments were purified with the PCR Purification Kit 
(Qiagen). DNA fragments were extracted from agarose gels using the QIAquick 
Gel Extraction Kit (Qiagen).  
3.2.2.2  Analyzing DNA 
DNA restriction digest was performed using 10 units of the appropriate 
restriction endonuclease per one µg of DNA. DNA fragments were separated 
using 0.8-2% agarose gels containing 0.01mg/ml ethidium bromide at 90V. 
Agarose gels were scanned with a Lumi-imager (Boehringer). 
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3.2.2.3 Amplification of DNA 
DNA was amplified using polymerase chain reaction (PCR) with Taq-DNA 
polymerase (Qiagen) or Pfu Polymerase (Fermentas). Thermocycling was 
performed in a Gene Amp PCR System 9600 (Perkin Elmer). The template was 
denatured for 2 min at 95°C, followed by 35 cycles of denaturation (30 sec, 
95°C), annealing (45sec, 50-60°C) and elongation (30-120 sec, 72°C). After the 
elongation was completed by incubation for 15 min at 72°C, the reaction was 
cooled down to 4°C. 
3.2.2.4 Cloning of DNA 
DNA fragments were ligated using T4-DNA-ligase (Invitrogen) at room 
temperature for two hours or at 4°C overnight. When the vector and insert had a 
similar length, a molar ratio of 1:3 (vector : insert) was used. When vector and 
insert were not similar in length, a molar ratio of 1:1 or 1:2 was used. 
Transformation of DH5α competent bacterial cells (Invitrogen) was performed 
according to the manufacturer`s manual.  
3.2.2.5 Sequencing of DNA 
Cycle sequencing was performed in a Gene Amp PCR System 9600 (Perkin 
Elmer) using the BigDye Terminator Cycle Sequencing Ready Reaction Kit 
v.1.1 (Applied Biosystems). After purification of the sequencing reaction using 
Centrisept Spin Colums (Princeton Separations) 4 µl of the sample were mixed 
with 21 µl HighDye Formamid (Applied Biosystems) in 96-well plates (Applied 
Biosystems). Signal detection was carried out on an ABI PRISM 3130xl Genetic 
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Analyser equipped with Data Collection Software v3.0 (both Applied 
Biosystems). 
3.2.3 Working with RNA 
3.2.3.1 Isolation and analysis of RNA 
Total RNA was extracted from cultured cells using the RNeasy Protect Midi Kit 
(Qiagen). Purity and integrity of the RNA was assessed on the Agilent 2100 
bioanalyzer with the RNA 6000 Nano LabChip® reagent set (Agilent 
Technologies) according to the manufacturer`s recommendations. The RNA 
was quantified on NanoDrop (Peqlab) and then stored at −80 °C. 
3.2.3.2  Reverse transcription of RNA  
cDNAs were generated by using the Reverse Transcripton System from 
Promega. Reverse transcription was performed in 40µl reaction volume 
containing 2µg RNA. 
3.2.3.3 Real-time quantitative RT-PCR (TaqMan™) analysis  
Real-time quantitative RT-PCR analysis was performed with an ABI7900HT 
machine (Applied Biosystems). All reagents necessary for running a TaqMan™ 
RT-PCR assay were purchased from Applied Biosystems and used according 
to the manufacturer's instructions. TaqManTM analysis of the transcript for 
hABCG1-a and hABCG1b has been determined with Assays by Design 
(Applied Biosystems). All other transcripts have been specified with 
predesigned and optimized Gene Expression Assays (Applied Biosystems). 
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In detail 2,5 µL of single-stranded cDNA (10ng/µl) was mixed with 0.5µl Gene 
Expression Assay or Assay by Design, 5µl of TaqMan Universal PCR Master 
Mix and 2µl nuclease-free water. After the prepared mixture was loaded into a 
384 well-plate (Thermo Fast) the plate was sealed with a optical adhesive cover 
(Applied Biosystems) and then placed in the 384 Well Block of the ABI7900HT 
machine. The thermal cycling conditions were 2 min at 50 °C and 10 min at 95 
°C, followed by 40 cycles of 30 s at 97 °C and 1 min at 59.7 °C. Each sample 
was analyzed in duplicates. 
Relative quantitation was carried out with the Applied Biosystems software SDS 
2.2. In detail, gene expression values were calculated based on the 
comparative threshold cycle (Ct) method, in which RNA samples were 
designated as calibrators to which the other samples were compared. The Ct 
data for the analyzed gene and 18S rRNA in each sample were used to create 
δCt values (Ctgene – Ct18S rRNA). Thereafter, δδCt values were calculated by 
subtracting the δCt of the calibrator from the Ct value of each target. The RQs 
were calculated with the equation: RQ = 2–δδCt. For calculating the RQ of the 
analyzed gene mRNA in CLA treated compared with untreated macrophages, 
untreated samples were designated as calibrators. The standard deviations 
(SDs) for δCt and δδCt values were calculated from the single Ct values with the 
equation: SDδCt = (SD12 + SD22). δCt values >25 were selected as the cut-off 
for absence of expression. All data are expressed as changes in transcript 
levels relative to the control group. 
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3.2.3.4 DNA-Microarray analysis  
Gene expression profiles were determined using U133 Plus 2.0 GeneChips, 
which cover more that 47.000 human transcripts. We had three RNAs from 
three healthy donors per condition and each isolated RNA was hybridized to a 
single microarray by the Kompetenzzentrum für Fluoreszente Bioanalytik in 
Regensburg.  
In a first step of gene array analysis expression signals for each transcript and 
comparisons between control and treated macrophages were calculated with 
the Affymetrix GCOS (gene chip operating software) 1.4 and Microsoft Excel 
(Microsoft Corp., Redmond, WA). Genes were picked out, which showed similar 
significant regulation in each replicate per condition. In a second step 
microarray data were analyzed on single probe level using the Genomatix 
microarray analysis software ChipInspector. This method uses the significance 
analysis of microarrays (SAM) algorithm [77; 78]. After total intensity 
normalization of the microarrays we used the exhaustive comparison mode for 
analyzing the raw data. Subsequently a SAM algorithm with a false discovery 
rate of 0% and probe coverage of three was used to identify significantly 
regulated genes. Finally the results of step one and two were combined and 
biomedical pathway analysis of the resulting genes was performed. All data are 
expressed as fold changes in transcript levels relative to the control group.  
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3.2.4 Working with proteins 
3.2.4.1 Isolation and quantification of proteins 
For protein isolation cells were washed in 1xPBS and lysed in RIPA buffer 
(Roche). Protein concentration was determined using the BCA protein assay 
reagent (Pierce Biotechnology). 
3.2.4.2 Western blot analysis 
Equal amounts of total cellular protein were denaturated at 70°C for 10 min after 
addition of NuPage-Sample Buffer (Invitrogen) and were separated on 4-12% 
NuPage-SDS-gels (Invitrogen). After protein transfer on polyvinylidene fluoride 
(PVDF) membranes (Roche), membranes were blocked in 3% BSA/PBS for 1h 
and incubated with a 1:1000 dilution of primary polyclonal anti-SREBP-1 
antibody (Santa Cruz) or incubated with a dilution of 1:1000 primary monoclonal 
anti-ABCG1 antibody (Gene Tex) for 1h. Both antibodies were detected using a 
1:20000 dillution of a peroxydase conjugated anti-rabbit immunoglobulin G 
(Dianova). Proteins were visualized with the ECL Plus™ Western Blotting 
Detection System (Amershan) on film. 
3.2.4.3 Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were prepared with NE-PER-Kit (Pierce).  In vitro synthesized 
human SREBP-1c was generated using the pCMV-SREBP-1c plasmid 
described before and the TNT Quick Coupled Transcription and Translation 
System from Promega. EMSAs were performed with the digoxygenin (DIG) gel 
shift kit 2nd generation for 3`-end labelling of oligonucleotides (Roche). The used 
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oligomers 5`-ACTGCCAGGGGTCACCCCACACCGGTGCTGTT-3` and 5`-
AACAGCACCGGTGTGGGGTGACCCCTGGCAGT-3`contained the predicted 
SRE site [32]. These oligos were annealed, labelled and used in gel shift 
reactions. For electrophoretic separation retardation gels (6%) purchased from 
Invitrogen were used. Blotting was performed using a Biorad electroblotting 
system. Chemiluminescence of DIG labelled DNA was detected as described in 
the manufacturer`s instructions. 
 
3.2.5 Cholesterol efflux assays 
Cholesterol efflux assays were performed as described [79]. In detail, 850000 
monocytes were seeded in 6-well plates and incubated for 96 h in M-SFM 
containing 50ng/ml MCSF for differentiation of macrophages. Then, 
macrophages were incubated for 24h in RPMI containing 0.2% BSA and 
15µg/ml D5-Cholesterol (Larodan) for 24h. Cells were then rinsed with PBS and 
incubated in RPMI containing 0.2% BSA and 10µM t9,t11-CLA or EtOH as 
control for another 24 h. Cells were rinsed again with PBS and incubated with or 
without 10µg/ml ApoAI or 100µg/ml HDL2 or 100µg/ml HDL3 and +/-10µM 
t9,t11-CLA or EtOH as control. Efflux of D5-cholesterol from cells was measured 
by the appearance of label in the medium. In detail, the cholesterol efflux was 
calculated as percent fraction of the D5-cholesterol in media over the total D5-
cholesterol (D5-cholesterol in media + D5-cholesterol in cells). The efflux was 
calculated in the presence of ApoAI, HDL2 or HDL3 with or without t9,t11-CLA 
minus the efflux in the presence of BSA and in absence of the respective 
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agonist (ApoAI, HDL2 or HDL3). Cholesterol was quantified by electrospray 
ionization tandem mass spectrometry (ESI-MS/MS) in the positive ion mode 
after acetylation as described [80]. D5-cholesterol was monitored by a SRM 
transition of m/z 451.4 > 374.3. Samples were quantified using the analytical 
setup and the data analysis algorithms described by Liebisch et al [81]. 
 
3.2.6 Statistical analysis 
Statistical analysis was examined with the independent student`s t-test of the 
MedCalc software for Windows. Significance levels of differences were set to 
p<0.05 (*) and p<0.01(**). 
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4 Results 
4.1 Gene expression analysis of t9,t11-CLA treated primary 
human monocytes derived macrophages with DNA-
microarrays 
To determine the effects of t9,t11-CLA on global gene expression the 
expression of more than 47000 known human transcripts was analyzed using 
Human Genome U133 Plus 2.0 Affymetrix DNA-microarrays. In vitro for 4 days 
in MCSF differentiated monocyte derived macrophages from three healthy 
donors were treated with 100µM t9,t11–CLA and ethanol as control (figure 13). 
         
Figure 13: Experimental strategy for mRNA expression analysis of CLA treated primary 
macrophages from three healthy volunteers. MCSF, macrophage colony stimulating factor. 
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RNA was isolated and six independent RNA samples (3 control RNAs and 3 
RNAs from t9,t11-CLA treated macrophages) were separately hybridized on 
DNA-microarrays by the Kompetenzzentrum für Fluoreszente Bioanalytik in 
Regensburg. DNA-microarrays were analyzed as described in the methods 
section. In the first step of our analysis genes where selected, which showed a 
similar significant regulation in each of the t9,t11-CLA treated replicates. This 
analysis revealed more than 100 regulated genes. With the second step, the 
analysis of the microarrays on a single probe level with the Genomatix 
microarray analysis software ChipInspector, 49 differently regulated transcripts 
could be identified. Combining of both analyses finally revealed 36 transcripts, 
which were significantly regulated in control versus t9,t11-CLA treated 
macrophages. Several genes of fatty acid synthesis, β-oxidation and also target 
genes of the PPAR family were present. Most importantly, as indicated in table 
1 target genes of the nuclear transcription factor SREBP and ABCG1 were 
significantly induced [40; 44]. SREBP-1c, its target genes such as fatty acid 
synthase (FASN), stearoyl-CoA desaturase (SCD), as well as SREBP-2 target 
genes such as 7-dehydrocholesterol reductase, 3-hydroxy-3-methylglutaryl-CoA 
reductase and synthase 1 were significantly induced. Remarkably, the CLA 
isomer had strongest effects on the expression of the ATP-binding cassette 
transporter G1, which was induced 4.4 fold (3.2-6.5 fold). These results indicate 
that t9,t11-CLA has a strong effect on gene expression related to lipid 
metabolism in primary human monocyte derived macrophages. 
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Changes of gene expression (Affymetrix DNA-microarrays)   
Gene Symbol Mean expression Mean FC 
    Control t9,t11-CLA 
SREBP-1c target genes    
Acetoacetyl-CoA synthetase AACS 152 (132-168) 1.5 (1.4-1.5) 
Fatty acid synthase FASN 177 (157-196) 3.1 (2.1-4.0) 
Stearoyl-CoA desaturase  SCD 4356 (3553-4771) 2.0 (1.6 -2.0) 
Sterol regulatory element binding protein 1c SREBP-1c 207 (140-247) 2.0 (1.7-2.5) 
SREBP-2 target genes    
7-Dehydrocholesterol reductase DHCR7 308 (261-352) 2.1 (1.7-2.6) 
Farnesyl-diphosphate farnesyltransferase 1 FDFT1 1208 (1006-1335) 1.4 (1.1-1.6) 
Farnesyl diphosphate synthase FDPS 865 (822-898) 1.5 (1.4-1.5) 
3-Hydroxy-3-methylglutaryl-CoA reductase HMGCR 508 (428-637) 1.6 (1.4-1.7) 
3-Hydroxy-3-methylglutaryl-CoA synthase 1  HMGCS 146 (128-165) 1.9 (1.6-2.3) 
Insulin induced gene 1 INSIG1 1880 (1601-2246) 1.7 (1.4-2.0) 
Low density lipoprotein receptor  LDLR 557 (467-628) 1.8 (1.5-2.1 
MID1 interacting protein 1 MIDIP1 227 (218-233) 1.8 (1.5-2.1) 
    
ABC-Transporter    
ATP-binding cassette transporter G1 ABCG1 204 (91-358) 4.4 (3.2-6.5) 
Table 1: Genes, whose transcripts were increased in 3 probands after stimulation with 100µM 
t9,t11-CLA for 24h. The expression signals are given for the untreated samples. The fold 
change (FC) of gene expression between samples and controls is indicated. 
 
4.2 Verification and further analysis of the candidate genes in 
primary human monocyte derived macrophages and the 
myeloid cell line THP-1 
 
To validate the results obtained with DNA-microarrays with an independent  and 
more sensitive technique, TaqManTM RT-PCR was performed for the candidate 
genes. All genes could be verified in t9,t11-CLA treated primary human 
monocyte derived macrophages (table 2). Fatty acid synthase, stearoyl-CoA 
desaturase, 7-dehydrocholesterol reductase, HMG-CoA reductase and HMG-
CoA synthase 1 were strongly induced (2.4-3.5 fold), whereas farnesyl-
diphosphate farnesyltransferase 1 was not clearly activated (1.3 fold). SREBP-
Results 
 - 42 - 
1c  and ABCG1 were found increased in each replicate 1.2-2.0 fold and 3.1-7.1 
fold. 
For further confirmation of the microarray results stimulation experiments with 
t9,t11-CLA were repeated in PMA differentiated THP-1 cells and mRNA 
expression was analyzed with TaqManTM RT-PCR. All candidate genes showed 
a clear up-regulation except MID1 interacting protein 1, which was induced only 
about 1.3 fold. Notably SREBP-1c and ABCG1 were found induced 2.0 fold and 
4.8 fold, respectively.   
To compare the effects of single CLA-isomers on gene expression among each 
other, we incubated MCSF differentiated monocyte derived macrophages from 
the three healthy donors (figure 13) and the THP-1 cells with c9,t11- and 
t10,c12-CLA and analyzed the mRNA expression. In contrast to t9,t11-CLA 
treated cells, gene expression of candidate genes in c9,t11-CLA and t10,c12-
CLA stimulated primary human monocyte derived macrophages was mainly 
unchanged, except for 3-hydroxy-3-methylglutaryl-CoA reductase and synthase 
(table 2). In c9,t11-CLA and t10,c12-CLA treated THP-1 cells most of the genes 
were decreased or unchanged, clearly suggesting and isomer specific effect of 
t9,t11-CLA on gene expression in human macrophages. 
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Changes of gene expression (TaqMan RT-PCR)      
Gene Symbol FC            
  t9,t11-CLA  c9,t11-CLA t10,c12-CLA 
    THP1 Proband 1-3 THP1 Proband 1-3 THP1 Proband 1-3 
SREBP-1c target genes        
Acetoacetyl-CoA synthetase AACS 1.6 2.0 (1.5-2.7) 1.0 1.7 (1.3-2.2) 0.9 1.1 (0.5-1.8) 
Fatty acid synthase FASN 1.9 3.1 (2.1-4.0) 0.7 1.3 (1.2-1.5) 0.6 0.9 (0.7-1.0) 
Stearoyl-CoA desaturase SCD 4.9 3.4 (3.0-3.8) 1.0 0.9 (0.5-1.4) 0.8 0.7 (0.3-0.9) 
SRE binding protein 1c SREBP-1c 2.0 1.7 (1.2-2.0) 0.8 0.9 (0.7-1.0) 0.7 0.7 (0.6-0.8) 
SREBP-2 target genes        
7-Dehydrochol. reductase DHCR7 5.5 3.5 (1.7-5.1) 1.0 1.5 (0.5-2.4) 0.9 1.1 (0.5-2.2) 
FDF-transferase 1 FDFT1 2.5 1.3 (1.2-1.4) 1.2 1.1 (0.9-1.2) 0.9 1.0 (0.7-1.4) 
FDF-synthase FDPS 1.7 2.1 (1.3-3.5) 0.8 1.5 (1.0-2.5) 0.8 1.1 (0.4-2.1) 
HMG-CoA reductase HMGCR 1.6 3.5 (2.3-4.6) 1.0 2.5 (1.7-3.2) 0.9 2.1 (1.5-2.7) 
HMG-CoA synthase 1  HMGCS 3.7 2.4 (2.1-2.7) 0.9 2.0 (1.2-3.0) 0.9 1.6 (0.6-2.7) 
Insulin induced gene 1 INSIG1 3.0 1.9 (1.7-2.3) 1.1 1.2 (0.7-1.6) 1.0 1.1 (0.9-1.6) 
LDL receptor  LDLR 3.0 1.8 (1.7-1.9) 1.1 1.3 (1.1-1.4) 1.2 1.1 (0.8-1.4) 
MID1 interacting protein 1 MIDIP1 1.3 1.8 (1.1-2.7) 1.1 1.3 (0.8-2.0) 1.0 1.1 (1.0-1.2) 
        
ABC-Transporter        
ABC transporter G1 ABCG1 4.8 4.5 (3.1-7.1) 1.3 1.2 (0.9-1.6) 0.9 1.0 (0.8-1.3) 
Table 2: T9,t11-, c9,t11-, t10,c12-CLA induced mRNA expression in THP-1 cells and primary 
human macrophages from three healthy donors. Cells were treated 100µM for 24h with the 
appropriate substance and EtOH as control. Gene expression was monitored using TaqManTM 
RT-PCR standardized to 18S rRNA as reference. The fold change (FC) in THP-1 cells and the 
mean FC in primary human macrophages of gene expression between samples and controls is 
indicated. 
 
4.3 Analysis of SREBP-1c and ABCG1 protein expression in 
t9,t11-CLA treated human macrophages 
T9,t11-CLA induced SREBP-1c transcription 2.0 fold and 1.7 fold and ABCG1 
transcription 4.8 fold and 4.5 fold in the THP-1 cell line and primary 
macrophages. To verify these results on the protein level, THP-1 cells were 
differentiated to macrophages with PMA and stimulated with 100µM t9t11-CLA 
or ethanol as control for 24h. Isolated proteins were used for western blot 
analysis.  
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As indicated figure 14, expression of the premature form pSREBP-1 was 
increased as well as expression of its nuclear and transcriptional active form 
SREBP-1c.  Protein levels of ABCG1 were also elevated after treatment of cells 
with t9,t11-CLA. These findings are in good agreement with the identified 
transcriptional changes. 
                               
Figure 14: T9,t11-CLA induced protein expression of SREBP-1c and ABCG1. THP-1 
macrophages were treated with 100µM t9,t11-CLA or EtOH as control for 24h. 
 
4.4 Analyis of t9,t11-CLA mediated activation of ABCG1 
The interesting finding that t9,t11-CLA, but not c9,t11- and t10,c12-CLA induce 
transcription of ABCG1 and SREBP-1c suggests that ABCG1 is induced via 
SREBP-1c. To investigate this hypothesis, mRNA expression of the isoform 
hABCG1-a of ABCG1 was determined with TaqManTM RT-PCR in human 
macrophages. T9,t11-CLA significantly induced the transcription of hABCG1-a 
in the THP-1 cell line and in primary human monocyte derived macrophages 
Results 
 - 45 - 
from 2.3 to 5.8 fold (figure 15). In macrophages stimulated with c9,t11-CLA 
transcription was decreased (0.9-0.5 fold) apart from proband 1, where mRNA 
expression was increased 1.8 fold. Treatment with t10,c12-CLA lead to changes 
between 0.6 and 0.7 fold. These results show that transcription of hABCG1-a is 
strongly increased in t9,t11-CLA, but not in c9,t11- and t10,c12-CLA stimulated 
cells. 
 
     
Figure 15: T9,t11-, c9,t11, t10,c12-CLA induced mRNA expression of hABCG1-a in THP-1 cells 
and primary human monocyte derived macrophages from three probands. Cells were treated 
100µM for 24h with the appropriate substance and ethanol as control. Gene expression was 
monitored using TaqManTM RT-PCR standardized to 18S rRNA as reference. p<0.05(*). 
 
The promoter of hABCG1-a contains a consensus sequence for a putative 
SREBP response element (SRE) at position -660/-648bp with the sequence 5`-
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GTCACCCCAC-3 [32]. This putative SRE element is very similar to other 
described SRE promoter sequences of SREBP target genes (table 3). 
 
Gene Symbol SRE promoter sequence (5`-3`)  Reference 
                          
             
ATP-binding cassette transporter G1 ABCG1 G T C A C C C C A C [32] 
Fatty acid synthase FAS G C C A C G C C A C [82] 
(2 binding sites)  G T C A G C C C A T  
Glycerol-3-phosphate acyl transferase GPAT C T C A G C C T A G [83] 
(3 binding sites)  C T C A C C C C A G  
  G A C A C C C C A G  
3-Hydroxy-3-methylglutaryl-CoA synthase 1  HMGCS C T C A C C C C A C [84] 
(2 binding sites)  G C C A C C C T A C  
Low density lipoprotein receptor  LDLR A T C A C C C C A C [85] 
Sterol regulatory element binding protein 1c SREBP-1c C T C A C C C C A G [52] 
                          
Table 3: SRE binding sites of selected SREBP responsive genes and putative SRE sequence of 
ABCG1. 
 
To characterize the activation of the hABCG1-a promoter, two deletion 
constructs were assayed in reporter gene assays. RAW 264.7 macrophages 
and plasmids containing the 2912/+50bp or -957/+50bp region of the hABCG1-
a promoter driving a luciferase gene were used. Both constructs contain the 
consensus sequence of the putative SRE (figure 16). T9,t11-CLA stimulation of 
transfected macrophages resulted in a concentration dependent activation of 
both promoter constructs. 
For further analysis of the regulatory region of the hABCG1-a promoter, the 
activity of two shorter deletion constructs with -457/+50bp and -234/+50bp 
length was determined, which do not contain the SRE (figure 2). Treatment with 
100µM t9, t11-CLA did not affect the activity of these two promoter constructs 
lacking the SRE. 
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Figure 16: Correlated luciferase activity (X-fold; EtOH-Control=1) of RAW 264.7 cells transiently 
transfected with the indicated gene reporter reporter plasmids. Cells were treated with the 
appropriate concentration of t9,t11-CLA or EtOH as control for 36h.  
 
To confirm that ABCG1 can be activated by SREBP-1 and to determine the 
isoform inducing the SRE, the -957/+50bp ABCG1 promoter construct was 
cotransfected with expression constructs of the two nuclear forms SREBP-1a 
and SREBP-1c. Cotransfection with pCMV-nSREBP-1c significantly increased 
luciferase activity (2.5 fold), whereas cotransfection with pCMV-nSREBP-1a 
showed no change in luciferase activity, indicating that ABCG1 can be 
specifically activated by SREBP-1c in macrophages (figure 17). 
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Figure 17: Correlated luciferase activity of RAW 264.7 macrophages transiently transfected with 
a -957/+50bp-hABCG1-a luciferase reporter plasmid and expression plasmids for SREBP-1a or 
SREBP-1c. Cells were cotransfected for 36h. p<0.01(**). 
 
To analyze the functionality of the putative SRE motif in the hABCG1-a 
promoter as independent transcriptional regulator, the gene construct 
pTK3xSRE was developed (figure 18). It contains three copies of the specific 
SREBP responsive element from hABCG1-a in front of the minimal thymidine 
kinase (TK) promoter driving the luciferase gene. Cotransfection of RAW 264.7 
cells with pCMV-nSREBP-1c, significantly increased reporter gene activity. 
Notably, even cotransfection of 1ng SREBP-1c led to a significant 2 fold 
increase in luciferase activity. Cotransfection with increasing amounts of the 
transcription factor led to 5-20 fold enhanced activities of the gene reporter, 
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demonstrating that the SRE motif markedly contributes to SREBP-1c mediated 
induction of the ABCG1 promoter. 
         
 
Figure 18: Correlated luciferase activity (X-fold; Control=1) of RAW 264.7 macrophages 
transiently transfected with pTK-3xSRE and cotransfected with the indicated amount of pCMV-
SREBP-1c. p<0.05(*); p<0.01(**). 
 
To determine whether SREBP-1c binds to the ABCG1 SREBP responsive 
element, oligonucleotide probes containing the putative SRE site from the 
hABCG1-a promoter were used to perform electrophoretic mobility shift assays. 
The DNA-protein complex could be detected as shifted band in the presence of 
a nuclear extracts from THP-1 macrophages (figure 19). Competition with a 50-
fold excess of the unlabeled probe revealed sequence specificity of the DNA 
protein binding reaction, because the shifted band was markedly reduced. The 
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nuclear extract incubated with an antibody did not produce a supershift band, 
but nearly abolished the shifted band. This result most likely indicates that the 
antibody disrupted the DNA-protein interaction, resulting in reduction in the 
amount of the characteristic gel shift but no supershift. In the presence of in 
vitro synthesized SREBP-1c a DNA protein complex could be detected 
approximately at the same height as in the presence of the nuclear extract 
confirming that SREBP-1c binds to the SRE element located in the hABCG1-a 
promoter.  
                   
Figure 19: Electrophoretic mobility shift assay using a consensus ABCG1 SRE oligonucleotide, 
a nuclear extract from THP-1 cells, a unlabeled competition oligo in 50fold excess, a SREBP-1 
antibody and in-vitro synthesized SREBP-1c as indicated.  
4.5 Analyis of t9,t11-CLA mediated activation of SREBP-1c 
LXR is a major activator of SREBP-1c [86], hence we tested the hypothesis  
that t9,t11-CLA is activator of LXR. Therefore mRNA expression of LXRα and 
its target genes in primary macrophages and cell line macrophages treated for 
24h with 100µM t9,t11-CLA was determined with TaqManTM RT-PCR. Since 
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several LXR target genes can also be induced by SREBP-1c, we also analyzed 
transcription of genes that are exclusively activated by LXR. 
As shown in table 4, a 2.3 fold and 1.7 fold up-regulation of Liver X receptor α in 
primary macrophages and cell line macrophages could be detected. The LXR 
target gene ABCA1 was significantly activated 2.4 and 1.9 fold, whereas 
phospholipid transfer protein was induced only in primary macrophages, but not 
in THP-1 cells. VEGF was activated 7.8 fold in primary macrophages. 
Interestingly, hABCG1-b, the LXR-controlled form of ABCG1, showed a lower 
response to the CLA isomer compared to the SREBP-1c regulated isoform 
hABCG1-a (4.4 fold versus 6.6 fold in primary macrophages and 1.3 fold versus 
3.3 fold in THP-1 cells, respectively).  
Changes in gene expression (TaqMan RT-PCR)    
Gene Symbol FC    
  t9,t11-CLA  
    THP1 Proband 1-3 
Liver X receptor α LXRα  1.7  2.3 (2.2-2.5) 
Liver X receptor target genes    
ATP binding cassette transporter A1 ABCA1  1.9  2.4 (2.2-2.5) 
ATP binding cassette transporter G1 isoform a hABCG1-b  1.3 4.4 (4.2-4.6) 
Phospholipid transfer protein PLTP  1.0 2.0 (1.9-2.2) 
Vascular endothelial growth factor VEGF  1.5  7.8 (7.4-8.3) 
SREBP-1c target gene    
ATP binding cassette transporter G1 isoform b hABCG1-a  3.3 6.6 (6.4-6.8) 
Table 4: T9,t11-CLA induced mRNA expression in human macrophages. Cells were treated 
100µM t9,t11-CLA and ethanol as control for 24h. Gene expression was monitored using 
TaqManTM RT-PCR standardized to 18S rRNA as reference. FC, fold change. 
 
To analyze the potential LXR dependent induction of SREBP-1c, the activity of 
its promoter region was investigated with gene reporter assays. Therefore, 
THP-1 cells were transfected with plasmids containing the promoter region from 
-422bp to -186bp of SREBP-1-c. This region harbours two LXR binding sites at 
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positions -349/-334bp and -298/-283bp. Treatment of transfected cells with 
100µM t9,t11-CLA resulted in a significant activation of the reporter gene, 
whereas CLA treatment of cells transfected with constructs containing 
mutations in the first, second, or both LXR binding sites, did not significantly 
affect promoter activity (figure 20). These results confirm that t9,t11-CLA 
activates SREBP-1c via LXR in human macrophages. 
 
Figure 20: Correlated luciferase activity (X-fold; EtOH-Control=1) of THP-1 cells transiently 
transfected with the indicated gene reporter reporter plasmids. Cells were treated with 100µM 
t9,t11-CLA or EtOH as control for 36h. p<0.01(**). 
 
4.6 Concentration range of t9,t11-CLA  
To determine the effective concentration range by that the CLA isomer induces 
gene expression, primary macrophages were treated with doses from 5µM to 
100µM of t9,t11-CLA for 24h and mRNA expression of LXRα, SREBP-1c, 
ABCG1 and ABCA1 was analyzed with TaqManTM RT-PCR. For determination 
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of ABCG1 transcription a gene expression assay detecting both, hABCG1-a 
and hABCG1-b was used. 
As indicated in figure 21 the CLA-isomer activated transcription of LXRα, 
SREBP-1c and ABCG1 in a dose dependent manner (figure 21). ABCA1 
transcription was activated 2.4-and 2.6-fold with the lower doses, whereas 
treatment of cells with higher doses induced ABCA1 mRNA expression only 
2.0-fold. Notably, a dose of 10µM led to a 2.0-fold induction of SREBP-1c and 
ABCG1, and to a 2.6-fold induction of ABCA1 indicating that especially the 
physiological levels of CLA significantly influence gene expression in human 
macrophages [87]. 
 
 
Figure 21: T9,t11-CLA induced mRNA expression in primary macrophages. Cells were treated 
with the indicated CLA dose and ethanol as control for 24h. Gene expression was monitored 
using TaqManTM RT-PCR standardized to 18S rRNA as reference.  
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4.7 Effects of t9,t11-CLA on ABCA1 and ABCG1 mediated 
cholesterol efflux 
 
Since ABCG1s and ABCA1s function is export of cholesterol, we examined 
ApoAI and HDL specific cholesterol efflux of human macrophages after 
treatment with t9,t11-CLA. Therefore, primary macrophages were loaded with 
labeld cholesterol and treated with 10µM t9,t11-CLA. Cholesterol efflux was 
determined with electrospray ionization tandem mass spectrometry (ESI-
MS/MS). This dose of CLA was selected, because using this concentration 
resulted in a significant induction of ABCA1 and ABCG1 mRNA expression. In 
addition, the dose of 10µM is within the physiological range of CLA in humans 
[87]. T9,t11-CLA significantly induced the efflux of cholesterol to ApoAI as 
acceptor particle, mediated by ABCA1, as well as to HDL2 and HDL3 as 
acceptor particles, mediated by ABCG1 (figure 22). ApoAI specific cholesterol 
export increased from 0,5% to 2,5%. HDL2 specific efflux was augmented from 
39% to 63% and HDL3 specific efflux from 30% to 40% after treatment of the 
cells with 10µM t9,t11-CLA. Interestingly, the ABCA1 mediated cholesterol 
efflux was more effected by the CLA isomer than the ABCG1 mediated efflux. 
These results indicate that the increase in mRNA levels of ABCA1 and ABCG1 
induced by t9,t11-CLA parallels with the functional response of cholesterol 
efflux in human macrophages. 
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Figure 22: Percent of ApoAI, HDL2 or HDL3 specific cholesterol efflux in the presence of 10µM 
t9,t11-CLA or EtOH as control. 
4.8 Summary of the results 
In summary, t9,t11-CLA treatment of human macrophages leads to activation of 
the following regulatory cascade (figure 23). The CLA isomer activates LXRα, 
which directly induces ABCG1, ABCA1 and SREBP-1c. SREBP1-c activates 
ABCG1 via binding in its regulatory region. The transcriptional activation of the 
ABC transporters A1 and G1 parallels with the functional response of 
cholesterol efflux in human macrophages.  
 
Figure 23: T9,t11-CLA induced transcriptional and functional cascade. 
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5 Discussion 
5.1 Isomer specific effects of CLA on macrophage gene 
transcription 
This study shows that the single isomers t9,t11-CLA, c9,t11-CLA and t10,c12-
CLA have individual effects on gene expression in human macrophages. Large 
scale transcription profiling revealed an up-regulated gene cluster of SREBP 
target genes in t9,t11-CLA treated in vitro MCSF differentiated monocyte 
derived macrophages from three healthy donors. SREBP-1c, its target genes 
and SREBP-2 targets were induced, whereas SREBP-2 was not differently 
regulated in t9,t11-CLA treated macrophages.  
Almost all genes identified with DNA-microarrays could be verified with 
TaqManTM RT-PCR. Although farnesyl-diphosphate farnesyltransferase 1 
showed only a small increase in several samples, the overall tendency in all 
replicates was upregulation. Further analysis of t9,t11-CLA stimulated THP-1 
cells confirmed the results of the microarrays from primary human monocyte 
derived macrophages. Comparison of mRNA expression to c9,t11-CLA and 
t10,c12-CLA treated cells with TaqManTM RT-PCR showed that the effect of 
t9,t11-CLA on gene expression of candidate genes is clearly isomer dependent.  
The finding that t10,c12-CLA slightly decreases the transcription of SREBP-1c 
is also supported by microarray studies from Larosa et al [88]. They found 
significant reductions of SREBP-1c mRNA expression in white adipose tissue of 
t10,c12-CLA fed mice. Takahashi et al. showed that mice fed a CLA mixture 
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had an increased mRNA expression of δ-5 and δ-6 desaturases, and SREBP-1c 
in liver [89]. The used mixture was mainly made of the two major CLA isomers 
and a smaller amount of minor isomers, among them t9,t11-CLA. Our results 
show a clear induction of stearoyl-CoA desaturase, a δ-6 desaturase and 
SREBP-1c in t9,t-11-CLA stimulated macrophages, but treatment with the two 
major isomers did not affect or slightly decreased the expression of these 
genes. Shaomei et al. reported that a mixture consisting mostly of the two major 
isomers up-regulates the LDL receptor gene (LDLR) in the heptoma cell line 
HepG2 [90]. Ringseis and colleges expanded these findings and reported that 
LDLR transcription is selectively induced by t10,c12-CLA but not by c9,t11-CLA 
in HepG2 cells [91]. However, our results clearly demonstrate that the single 
isomers c9,t11-CLA and t10,c12-CLA are not potent inducers of LDLR 
expression, at least in macrophages.  
Although t9,t11-CLA is a CLA isomer of minor abundance, it seems to have 
stronger effects on specific cellular processes than its major dietary occurring 
isomers. This assumption is also supported by studies on CLA isomer specific 
treated human colon cancer cells. T9,t11-CLA has an much higher inhibitory 
effect on the growth of Caco-2 cells than c9,t11- or t10,c12-CLA [92]. 
Furthermore, t9,t11-CLA has as stronger anti-proliferative activity in SW480 and 
HT-29 cancer cells compared to c9,t11-CLA [93].  
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5.2 T9,t11-CLA mediated activation of ABCG1 
A surprising and interesting finding was that ABCG1 and SREBP-1c were 
significantly up-regulated in t9,t11- but not in c9,t11- and t10,c12-CLA treated 
macrophages. From these data we hypothesized  that ABCG1 is activated by a 
SREBP-1c dependent mechanism. The promoter of ABCG1, which is 
responsible for transcription of the isoform hABCG1-a, contains a putative 
SREBP responsive element (SRE) and contributes to macrophage specific 
expression of ABCG1 [32]. Isoform specific transcription analysis confirmed the 
assumption that the mRNA expression of hABCG1-a is induced by t9,t11-CLA, 
but not by c9,t11- and t10,c12-CLA. Statistical analysis provided a significant 
difference between the expression values of the hABCG1-a isoform for t9,t11-
CLA, c9,t11-CLA and t10,c12-CLA stimulated cells. 
Reporter gene assays with the deletion constructs -2912/+50bp and -957/+50bp 
of the hABCG1-a promoter containing the putative SRE in RAW 264.7 
macrophages showed a dose dependent increase of luciferase activity after 
t9,t11-CLA treatement, whereas the -457/+50bp and -234/+50bp promoter 
constructs lacking the SRE were not activated by t9,t11-CLA. Cotransfections 
with SREBP-1c expression plasmids caused significant induction of the ABCG1 
promoter by SREBP-1c but not by SREBP-1a. This finding is plausible, because 
SREBP-1c is the major isoform in human tissues and it is highly regulated 
compared to SREBP-1a. We conclude that SREBP-1a isoform has only a minor 
role in vivo. Additionaly, nSREBP-1a overexpression in the liver of transgenic 
mice lead to fatty livers with accumulated triglycerides and cholesterol. 
Inversely, overexpression of nSREBP-1c was found to produce a triglyceride-
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enriched fatty liver with no increase in cholesterol [43]. The reason for this might 
be SREBP-1c dependent activation of ABCG1 mediated cholesterol efflux. 
However, the finding that SREBP-1c, but not SREBP-1a stimulates the ABCG1 
promoter is also surprising. In experiments comparing the transcriptional 
efficiency of these two isoforms in the liver, the SREBP-1a isoform had higher 
potency compared to SREBP-1c, despite DNA binding of both isoforms was 
similar [94]. In contrast to the current work, which uses the macrophage model, 
these experiments were performed in liver cells. Thus, tissue specific function of 
transcription factors might explain the controversial findings.  
The binding of SREBP-1c in the promoter of hABCG1-a has been investigated 
with electrophoretic mobility shift assays. Kim et al. reported that SREBPs can 
bind to E-boxes, like all basic helix loop helix proteins, as well as to SRE 
sequences [95], which are present in the promoter of ABCG1. Since the 
deletion constructs lacking the SRE could not be activated in luciferase assays, 
it was very likely that the SRE in the promoter of ABCG1 is responsible for its 
activation through SREBP-1c. Another reason supporting this suggestion is that 
in the vicinity of the SRE a SP1-element exists, which is a cofactor of SREBP in 
most promoters [40]. Our EMSAs also confirmed that SREBP-1c binds to the 
ABCG1 SRE. In the presence of in vitro synthesized SREBP-1c a DNA-protein 
complex could be detected nearly at the same height as in the presence of a 
nuclear extract from THP-1 cells. SREBP-1c protein undergoes significant 
posttranslational modification including phosphorylation, acetylation, 
sumoylation and ubiquitination [96]. The nuclear extract was prepared from 
human cells, whereas the in vitro translated SREBP-1c was generated in rabbit 
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reticulocytes. Thus different posttranslational modifications might explain the 
minimal differences in the height of the shifted bands.  
5.3 T9,t11-CLA mediated activation of SREBP-1c 
The assumed activation of liver X receptor by t9,t11-CLA has been investigated 
with RT-PCR analysis of LXRα and its target genes in t9,t11-CLA treated 
macrophages. The initially analyzed genes FASN, LDLR and SCD are direct 
target genes of the transcription factors SREBP-1c and LXR and thus genes 
were analyzed that are induced by LXR but not by SREBP-1c [97-99]. 
Transcriptional analysis of candidate genes in t9,t11-CLA treated macrophages 
clearly demonstrated that the CLA isomer induces LXRα and its target genes. 
The suggested LXR dependent activation of SREBP-1c has been investigated 
with luciferase assays. A reporter gene plasmid containing the LXR regulated 
promoter region of SREBP-1c could be activated by t9,t11-CLA isomer, 
whereas its alternative forms with mutations in the first LXR binding site could 
not be activated. hLXR-2mut, a alternative form with a mutation in the second 
LXR element, could be slightly induced by t9,t11-CLA. This finding supports the 
findings from Oberkoffler and collegues, that the second LXR binding element 
has a minor role in SREBP-1c promoter activity compared to its first LXR 
binding site [75].  
As indicated in figure 24 two mechanisms could be estimated explaining the 
t9,t11-CLA mediated activation of LXRα. The CLA isomer could either be a 
ligand for LXR and thereby directly induce it or t9,t11-CLA could activate LXRα 
by a PPARγ dependent mechanism. 
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Figure 24: Two possible mechanisms for LXRα activation by t9,t11-CLA. 
 
It is very likely that the CLA isomer activates LXR directly, since the initial 
isomer specific analysis of candidate genes with RT-PCR showed that t9,t11- 
but not c9,t11- and t10,c12-CLA induces SREBP-1c and its target genes. If the 
CLA isomer would activate LXRα via PPARγ, SREBP-1c and its target genes 
should also be induced by c9,t11-CLA and t10,c12-CLA, which are PPAR 
ligands. In fact the two major isomers should induce SREBP-1c and its target 
genes a lot stronger than t9,t11-CLA, because it has been demonstrated that  
these CLA isomers are ligands for PPARα with a rank order of c9,t11-
CLA>t10,c12-CLA>t9,t11-CLA in rat heptoma cells. C9,t11-CLA has even been 
described to be one of the most avid fatty acids ever described as a PPARα 
ligand [100]. The hypothesis that the CLA isomer activates LXRα directly is also 
supported by several studies showing that PPAR induction leads to SREBP-1c 
and SREBP-2 inhibition. Overexpression of PPARα and γ in human embryonic 
kidney 293 kidney cells inhibited LXR induced SREBP-1c promoter activity 
through a reduction of LXR/RXR complex formation [101]. PPARα activation in 
the rat heptoma cell line Fao led to an inhibited processing of the premature 
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SREBP-2 protein and thus to reduced levels of nuclear SREBP-2 [102]. 
Incubation of HepG2 and Caco-2 cells with the PPARγ agonist Troglitazone 
diminished nuclear SREBP-2 amounts and mRNA expression of SREBP-2 
target genes [103]. Since in our experiments t9,t11-CLA treatment led to an 
increase of SREBP-1c in promoter activity, transcription and protein levels, and 
to an upregulation of SREBP-2 target genes it is implausible that t9,t11-CLA 
activates LXRα via PPARγ. 
5.4 Effects of CLA isomers on lipid metabolism 
The known biological effects of CLA isomers on lipid metabolism are 
controversial. Most studies are investigating molecular and physiological effects 
of the major dietary forms of conjugated linoleic acid, c9,t11-CLA and t10,c12-
CLA. Our study compares the effects of these two major CLA isomers and the 
minor isomer t9,t11-CLA on macrophage gene expression. T9,t11-CLA was 
found to activate LXRα and SREBP-1c transcription.  
Granlund and colleges reported that treatment of adipocytes with t10,c12-CLA 
results in reduced expression of LXRα and SREBP-1c [104]. Surprisingly 
feeding obese mice with a t10,c12-CLA enriched diet did not affect LXRα 
expression, whereas c9,t11-CLA fed mice had a markedly reduced LXRα, 
SREBP-1c and ABCA1 expression [105].  
Interstingly, several studies have shown that c9,t11-CLA inhibits atherosclerosis 
development and progression. A c9,t11-CLA enriched diet led to significantly 
reduced plasma cholesterol and free fatty acid concentrations, but increased 
ApoAI concentrations in ApoE deficient mice [106]. Valeille et al found that 
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hyperlipidemic hamsters fed with a c9,t11-CLA rich oil have increased LXR 
dependent ABCA1 expression in the aorta and a reduced atherogenic outcome 
[107]. Moreover, supplementation with natural concentrations of c9,t11-CLA 
from milk fat led to higher plasma HDL cholesterol concentrations and 
increased ABCA1 gene expression resulting in increased reverse cholesterol 
transport in the hyperlipidemic hamster model [108]. However, neither c9,t11-
CLA, nor t10,c12-CLA had effects on ABCA1 transcription and cholesterol efflux 
to ApoA1 in THP-1 derived foam cells [109]. Although the findings are partly 
controversal, the overall physiological effect of c9,t11-CLA can be considered 
as anti-atherosclerotic.  
In contrast to c9,t11-CLA, t9,t11-CLA activates the transcription factors LXRα 
and SREBP-1c and thereby leads to enhanced ABCA1 and ABCG1 mediated 
cholesterol efflux in human macrophages. To estimate if the net effect of t9,t11-
CLA on lipid metabolism is beneficial, several different aspects of the induced 
network controlling intracellular cholesterol homeostasis must be discussed. 
These are summarized in figure 25. 
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Figure 25: T9,t11-CLA activated cascade and metabolic consequences. 
 
As a response to t9,t11-CLA treatment, transcription of LXR, SREBP-1c, its 
target genes and SREBP-2 target genes  are activated. LXR stimulates ABCA1 
directly and ABCG1 directly or via SREBP-1c and thereby promotes cholesterol 
efflux. SREBP-1c also enhances transcription of fatty biosynthesis genes, such 
as FASN, SCD and GPAT, which possibly lead to increased synthesis of fatty 
acids, triacylglycerides and phospholipids. Phospholipids are useful for 
formation of acceptor particles for ABCG1 mediated cholesterol efflux (HDL). 
SREBP-2 controlled genes, such as HMGCS and HMGCR, might lead to 
biosynthesis of cholesterol, which can be effluxed via ABCA1 and ABCG1 and 
when generated in excess inhibit SREBP-2 processing and thereby its own 
synthesis.   
Interestingly several studies have demonstrated that synthetic LXR agonists, 
have beneficial health effects and inhibit atherosclerosis development and 
progression in mice [74; 110; 111]. Despite the undesirable effects of LXR 
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mediated SREBP-1c induction (raised triacylglyceride levels) the net effect of 
LXR activation was found to be anti-atherogenic. Notably, the LXR agonist 
GW3965 was shown to decrease lesion area approximately 50% in both ApoE 
and LDLR knockout mice [74]. For this reason the overall effect of t9,t11-CLA 
could be considered as beneficial. However, to confirm these supposed 
beneficial effects, the levels of cholesterol and triacylglycerides after t9,t11-CLA 
treatment of macrophages could be determined in a follow up of our study.  
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6 Conclusion 
Conjugated linoleic acid (CLA) isomers are dietary fatty acids that modulate 
gene expression in many cell types. The aim of this work was to examine the 
function of the single c9,t11-, t10,c12- and t9,t11 CLA isomers on gene 
expression in human macrophages. Therefore, in vitro MCSF differentiated 
monocyte derived macrophages from three healthy donors and THP-1 
macrophages were incubated with these CLA-isomers and whole genome 
transcripts were analyzed with DNA-microarrays and realtime RT-PCR . T9,t11-
CLA, but not c9,t11- and t10,c12-CLA activated target genes of SREBP, 
SREBP-1c and ABCG1. This led to the hypothesis that ABCG1 is activated via 
SREBP-1c. Gene reporter assays with deletion constructs of the ABCG1 
regulatory region and cotransfections with a SREBP-1c expression plasmid in 
RAW 264.7 macrophages confirmed that t9,t11-CLA activates ABCG1 via 
SREBP-1c. EMSAs showed that SREBP-1c binds to a SREBP responsive 
element in the promoter of ABCG1. 
To answer the question by which mechanism this CLA isomer induces SREBP-
1c, transcription of liver X receptor (LXR) α, which is a major regulator of 
SREBP-1c, and its target genes was analyzed in t9,t11-CLA stimulated 
macrophages with RT-PCR. A significant induction of LXRα and its target genes 
was found. Gene reporter assays with a plasmid containing the LXR regulatory 
region of the SREBP-1c promoter confirmed that SREBP-1c is activated via 
LXRα by t9,t11-CLA.. 
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To determine the concentration range of t9,t11-CLA, human macrophages were 
treated with various doses of CLA and mRNA expression of target genes was 
analyzed. Incubation of human macrophages with 5 and 10µM t9,t11-CLA, 
which can be considered as physiological levels, led to a significant modulation 
of LXRα, SREBP-1c, ABCG1 and ABCA1. Finally the effects of 10µM t9,t11-
CLA on ABCA1 and ABCG1 expression were found to parallel with the 
functional response of cholesterol efflux in human macrophages.  
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9 Figures 
Figure 1: Formation of c9,t11-CLA in the digestive tracts of ruminant animals by 
Butyrivibrio fibrisolvens.  
Figure 2: CLA isomers of major and minor abundance. 
Figure 3: Domain organization of ABCG1 from [20]. 
Figure 4: Cholesterol efflux mediated by ABCA1 and ABCG1. PL,phospholipids; 
FC, free cholesterol; adapted from [28]. 
Figure 5: Exon configurations of the human ABCG1 transcripts and predicted 
proteins. aa, amino acid; adapted from [36].  
Figure 6: ABCG1 regulatory region, adapted from Langmann T., 
Habilitationsarbeit 2003. 
Figure 7: SREBP genes and isoforms. bHLH-LZ, basic helix loop helix leucine 
zipper, Pro, proline; Ser, serine; TA, trans activation. 
Figure 8: SREBP-2 and SREBP-1c controlled genes and metabolic pathways, 
from [43]. 
Figure 9: Regulation of SREBP-1a and SREBP-2 activation by proteolytic 
cleavage, from [43]. 
Figure 10: Promoter of SREBP-1c and its regulation. LXR-E, LXR binding 
element; SRE, SREBP response element; RXR, retinoid X receptor. 
Figure 11: LXR mediated activation of target genes, from [57]. 
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Figure 12: LXR and its target genes in reverse cholesterol transport, from [57]. 
Figure 13: Experimental strategy for mRNA expression analysis of CLA treated 
primary macrophages from three healthy volunteers. MCSF, macrophage 
colony stimulating factor. 
Figure 14: T9,t11-CLA induced protein expression of SREBP-1c and ABCG1. 
THP-1 macrophages were treated with 100µM CLA or EtOH as control for 24h. 
Figure 15: T9,t11-, c9,t11, t10,c12-CLA induced mRNA expression of hABCG1-
a in THP-1 cells and primary human monocyte derived macrophages from three 
probands. Cells were treated 100µM for 24h with the appropriate substance and 
ethanol as control. Gene expression was monitored using TaqManTM RT-PCR 
standardized to 18S rRNA as reference. p<0.05(*). 
Figure 16: Correlated luciferase activity (X-fold; EtOH-Control=1) of RAW 264.7 
cells transiently transfected with the indicated gene reporter reporter plasmids. 
Cells were treated with the appropriate concentration of t9,t11-CLA or EtOH as 
control for 36h.  
Figure 17: Correlated luciferase activity of RAW 264.7 macrophages transiently 
transfected with a -957/+50bp-hABCG1-a luciferase reporter plasmid and 
expression plasmids for SREBP-1a or SREBP-1c. Cells were cotransfected for 
36h. p<0.01(**). 
Figure 18: Correlated luciferase activity (X-fold; Control=1) of RAW 264.7 
macrophages transiently transfected with pTK-3xSRE and cotransfected with 
the indicated amount of pCMV-SREBP-1c. p<0.05(*); p<0.01(**). 
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Figure 19: Electrophoretic mobility shift assay using a consensus ABCG1 SRE 
oligonucleotide, a nuclear extract from THP-1 cells, a unlabeled competition 
oligo in 50fold excess, a SREBP-1 antibody and in-vitro synthesized SREBP-1c 
as indicated.  
Figure 20: Correlated luciferase activity (X-fold; EtOH-Control=1) of THP-1 cells 
transiently transfected with the indicated gene reporter reporter plasmids. Cells 
were treated with 100µM t9,t11-CLA or EtOH as control for 36h. p<0.01(**). 
Figure 21:T9,t11-CLA induced mRNA expression in primary macrophages. 
Cells were treated with the indicated CLA dose and ethanol as control for 24h. 
Gene expression was monitored using TaqManTM RT-PCR standardized to 18S 
rRNA as reference.  
Figure 22: Percent of ApoAI, HDL2 or HDL3 specific cholesterol efflux in the 
presence of 10µM t9,t11-CLA or EtOH as control. 
Figure 23: T9,t11-CLA induced transcriptional and functional cascade. 
Figure 24: Two possible mechanisms for LXRα activation by t9,t11-CLA. 
Figure 25: T9,t11-CLA activated cascade and metabolic consequences. 
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10 Tables 
Table 1: Genes, whose transcripts were increased in 3 probands after 
stimulation with 100µM t9,t11-CLA. for 24h. The expression signals are given 
for the untreated samples. The fold change (FC) of gene expression between 
samples and controls is indicated. 
Table 2: t9,t11-, c9,t11-, t10,c12-CLA induced mRNA expression in THP-1 cells 
and primary human macrophages from three healthy donors. Cells were treated 
100µM for 24h with the appropriate substance and EtOH as control. Gene 
expression was monitored using TaqManTM RT-PCR standardized to 18S rRNA 
as reference. The fold change (FC) in THP-1 cells and the mean FC in primary 
human macrophages of gene expression between samples and controls is 
indicated. 
Table 3: SRE binding sites of selected SREBP responsive genes and putative 
SRE sequence of ABCG1. 
Table 4: T9,t11-CLA induced mRNA expression in human macrophages. Cells 
were treated 100µM t9,t11-CLA and ethanol as control for 24h. Gene 
expression was monitored using TaqManTM RT-PCR standardized to 18S 
rRNA as reference. FC, fold change. 
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11 Abbreviations 
AACS Acetoacetyl-CoA synthetase 
ABC ATP-binding cassette 
Apo Apolipoprotein 
c9,t11 cis-9,trans-11 
CETP Cholesterol ester transfer protein 
CLA Conjugated linoleic acid 
Cyp7a1 Cholesterol 7-α-hydroxylase 
DHCR7 7-Dehydrochol. reductase 
DR Direct repeat 
EMSA Electrophoretic mobility shift assay 
ER Endoplasmatic Reticulum 
ESI-MS/MS Electrospray ionization tandem mass spectrometry 
FASN Fatty acid synthase 
FC Fold change 
FDFT1 FDF-transferase 1 
FDPS FDF-synthase 
h human 
HDL High density lipoprotein 
hHLH-LZ basic helix loop helix leucine zipper 
HMGCR HMG-CoA reductase 
HMGCS HMG-CoA synthase 1  
HSV Herpes simplex virus 
IBD Inflammatory bowel disease 
INSIG1 Insulin induced gene 1 
LDLR LDL receptor  
LPL Lipoprotein lipase 
Luc Luciferase 
LXR Liver X receptor 
LXR-E LXR binding element 
MCSF Macrophage colony stimulating factor 
MIDIP1 MID1 interacting protein 1 
n nuclear 
NFκB Nuclear factor κ B 
p premature 
PLTP Phospholipid transfer protein 
Pro Proline 
RXR Retinoid X receptor 
S1P Site 1 protease 
S2P Site 2 protease 
SAM Significance analysis of microarrays 
SCAP SREBP cleavage activating protein 
SCD Stearoyl-CoA desaturase 
SD Standard deviation 
Ser Serine 
SRE SREBP response element 
SREBP Sterol regulatory element binding protein 
 Abbreviations 
 - 86 - 
t10,c12 trans-10,cis-12 
t9,t11 trans-9,trans-11 
TA Trans activation 
TGF Transforming growth factor 
TK Thymidine kinase 
VEGF Vascular endothelial growth factor 
ZNF Zinc finger preotein 
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